Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months or since birth for infants; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months or since birth for and infants)
• •History of any meningitis infection, confirmed either clinically, serologically, or microbiologically
• •At high risk of meningococcal infection during the study
• •Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
• •Individual with active tuberculosis
• •History of Guillain-Barré syndrome
• •For Stage 3 infants: History of intussusception
• •Previous vaccination against meningococcal serogroups A, B, C, W, and/or Y with an investigational or marketed vaccine
• •For Stage 3 infants: receipt of the first dose of rotavirus vaccine less than 28 days before the first trial vaccination
• •NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.